{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:28Z","timestamp":1740107008525,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["K07CA132955","R21CA167202"],"award-info":[{"award-number":["K07CA132955","R21CA167202"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MD Anderson Cancer Center Clinical Trials Support Resource","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00520-020-05456-3","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T13:04:12Z","timestamp":1587387852000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study"],"prefix":"10.1007","volume":"29","author":[{"given":"Harrys A.","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla L.","family":"Warneke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich M.","family":"Sturgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica T.","family":"Foreman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Angelidakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest T.","family":"Hawk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica P.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"5456_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3322\/caac.21403","volume":"67","author":"HA Torres","year":"2017","unstructured":"Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V (2017) The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin 67:411\u2013431. https:\/\/doi.org\/10.3322\/caac.21403","journal-title":"CA Cancer J Clin"},{"doi-asserted-by":"publisher","unstructured":"Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA (2016) Association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst 108. https:\/\/doi.org\/10.1093\/jnci\/djw035","key":"5456_CR2","DOI":"10.1093\/jnci\/djw035"},{"key":"5456_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.oraloncology.2018.10.024","volume":"87","author":"JB Rangel","year":"2018","unstructured":"Rangel JB, Thuler LCS, Pinto J (2018) Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol 87:138\u2013143. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.10.024","journal-title":"Oral Oncol"},{"key":"5456_CR4","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2003-06-2145","volume":"103","author":"R Peffault de Latour","year":"2004","unstructured":"Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, Traineau R, Devergie A, Ribaud P, Esperou H, Gluckman E, Valla D, Socie G (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103:1618\u20131624. https:\/\/doi.org\/10.1182\/blood-2003-06-2145","journal-title":"Blood"},{"key":"5456_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4254\/wjh.v5.i6.332","volume":"5","author":"HA Torres","year":"2013","unstructured":"Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO (2013) Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 5:332\u2013335. https:\/\/doi.org\/10.4254\/wjh.v5.i6.332","journal-title":"World J Hepatol"},{"key":"5456_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","volume":"57","author":"P Mahale","year":"2012","unstructured":"Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA (2012) Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 57:1177\u20131185. https:\/\/doi.org\/10.1016\/j.jhep.2012.07.031","journal-title":"J Hepatol"},{"key":"5456_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep.29344","volume":"67","author":"HA Torres","year":"2018","unstructured":"Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS (2018) Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology 67:36\u201347. https:\/\/doi.org\/10.1002\/hep.29344","journal-title":"Hepatology"},{"key":"5456_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/JHC.S164568","volume":"5","author":"D Dandachi","year":"2018","unstructured":"Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA (2018) Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma 5:81\u201386. https:\/\/doi.org\/10.2147\/JHC.S164568","journal-title":"J Hepatocell Carcinoma"},{"key":"5456_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3324\/haematol.13756","volume":"94","author":"CA Ramos","year":"2009","unstructured":"Ramos CA, Saliba RM, de Padua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M (2009) Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94:249\u2013257. https:\/\/doi.org\/10.3324\/haematol.13756","journal-title":"Haematologica"},{"key":"5456_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/cncr.31146","volume":"124","author":"MP Economides","year":"2018","unstructured":"Economides MP, Amit M, Mahale PS, Hosry JJ, Jiang Y, Bharadwaj U, Sturgis EM, Torres HA (2018) Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. Cancer 124:960\u2013965. https:\/\/doi.org\/10.1002\/cncr.31146","journal-title":"Cancer"},{"doi-asserted-by":"publisher","unstructured":"Torres HA, Pundhir P, Mallet V (2019) Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.271","key":"5456_CR11","DOI":"10.1053\/j.gastro.2019.01.271"},{"issue":"Suppl 1","key":"5456_CR12","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/cid\/cis363","volume":"55","author":"BD Smith","year":"2012","unstructured":"Smith BD, Jorgensen C, Zibbell JE, Beckett GA (2012) Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis 55(Suppl 1):S49\u2013S53. https:\/\/doi.org\/10.1093\/cid\/cis363","journal-title":"Clin Infect Dis"},{"key":"5456_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","volume":"157","author":"BD Smith","year":"2012","unstructured":"Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW (2012) Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 157:817\u2013822. https:\/\/doi.org\/10.7326\/0003-4819-157-9-201211060-00529","journal-title":"Ann Intern Med"},{"key":"5456_CR14","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas DL (2019) Global elimination of chronic hepatitis. N Engl J Med 380:2041\u20132050. https:\/\/doi.org\/10.1056\/NEJMra1810477","journal-title":"N Engl J Med"},{"issue":"930\u2013939","key":"5456_CR15","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1016\/j.cgh.2018.08.080","volume":"17","author":"MH Eckman","year":"2019","unstructured":"Eckman MH, Ward JW, Sherman KE (2019) Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, Pangenotypic Treatment Regimens. Clin Gastroenterol Hepatol 17(930\u2013939):e939. https:\/\/doi.org\/10.1016\/j.cgh.2018.08.080","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5456_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/liv.13519","volume":"38","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S (2018) In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int 38:258\u2013265. https:\/\/doi.org\/10.1111\/liv.13519","journal-title":"Liver Int"},{"key":"5456_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/cid\/ciy098","volume":"67","author":"JA Barocas","year":"2018","unstructured":"Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP (2018) Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States. Clin Infect Dis 67:549\u2013556. https:\/\/doi.org\/10.1093\/cid\/ciy098","journal-title":"Clin Infect Dis"},{"key":"5456_CR18","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.bbmt.2015.07.033","volume":"21","author":"HA Torres","year":"2015","unstructured":"Torres HA, Chong PP, De Lima M, Friedman MS, Giralt S, Hammond SP, Kiel PJ, Masur H, McDonald GB, Wingard JR, Gambarin-Gelwan M (2015) Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant 21:1870\u20131882. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.033","journal-title":"Biol Blood Marrow Transplant"},{"key":"5456_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","volume":"16","author":"V Mallet","year":"2016","unstructured":"Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P, Ecil (2016) Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 16:606\u2013617. https:\/\/doi.org\/10.1016\/S1473-3099(16)00118-3","journal-title":"Lancet Infect Dis"},{"doi-asserted-by":"publisher","unstructured":"Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME (2018) Models to predict hepatitis B virus infection among patients with cancer undergoing systemic anticancer therapy: a prospective cohort study. J Clin Oncol:JCO2017756387. https:\/\/doi.org\/10.1200\/JCO.2017.75.6387","key":"5456_CR20","DOI":"10.1200\/JCO.2017.75.6387"},{"unstructured":"Centers for Disease Control and Prevention (2012) Hepatitis Risk Assessment (archived). https:\/\/web.archive.org\/web\/20120925161047\/https:\/\/www.cdc.gov\/hepatitis\/riskassessment\/index.htm. Accessed August 7, 2012","key":"5456_CR21"},{"unstructured":"Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW; Centers for Disease Control and Prevention (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61(RR-4):1\u201332","key":"5456_CR22"},{"doi-asserted-by":"publisher","unstructured":"Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6437","key":"5456_CR23","DOI":"10.1001\/jamaoncol.2018.6437"},{"key":"5456_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/cid\/ciw073","volume":"62","author":"MS Lyons","year":"2016","unstructured":"Lyons MS, Kunnathur VA, Rouster SD, Hart KW, Sperling MI, Fichtenbaum CJ, Sherman KE (2016) Prevalence of diagnosed and undiagnosed hepatitis C in a Midwestern Urban Emergency Department. Clin Infect Dis 62:1066\u20131071. https:\/\/doi.org\/10.1093\/cid\/ciw073","journal-title":"Clin Infect Dis"},{"key":"5456_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/cid\/ciw074","volume":"62","author":"YH Hsieh","year":"2016","unstructured":"Hsieh YH, Rothman RE, Laeyendecker OB, Kelen GD, Avornu A, Patel EU, Kim J, Irvin R, Thomas DL, Quinn TC (2016) Evaluation of the Centers for Disease Control and Prevention recommendations for hepatitis C virus testing in an Urban Emergency Department. Clin Infect Dis 62:1059\u20131065. https:\/\/doi.org\/10.1093\/cid\/ciw074","journal-title":"Clin Infect Dis"},{"key":"5456_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/jvh.12913","volume":"25","author":"G Angelidakis","year":"2018","unstructured":"Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA (2018) Universal screening for hepatitis C: a needed approach in patients with haematologic malignancies. J Viral Hepat 25:1102\u20131104. https:\/\/doi.org\/10.1111\/jvh.12913","journal-title":"J Viral Hepat"},{"key":"5456_CR27","first-page":"645","volume":"62","author":"Centers for Disease C, Prevention","year":"2013","unstructured":"Centers for Disease C, Prevention (2013) Locations and reasons for initial testing for hepatitis C infection\u2014chronic hepatitis cohort study, United States, 2006-2010. MMWR Morb Mortal Wkly Rep 62:645\u2013648","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5456_CR28","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.amepre.2017.01.033","volume":"53","author":"A Jemal","year":"2017","unstructured":"Jemal A, Fedewa SA (2017) Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med 53:e31\u2013e33. https:\/\/doi.org\/10.1016\/j.amepre.2017.01.033","journal-title":"Am J Prev Med"},{"unstructured":"United States Preventive Services Task Force (2017) Draft research plan for hepatitis C virus infection in adolescents and adults: screening. www.uspreventiveservicestaskforce.org\/Page\/Document\/draft-research-plan\/hepatitis-c-screening1. Accessed February 8, 2019","key":"5456_CR29"},{"key":"5456_CR30","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1200\/jop.2013.001215","volume":"10","author":"JP Hwang","year":"2014","unstructured":"Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS (2014) Hepatitis C virus screening in patients with cancer receiving chemotherapy. J Oncol Pract 10:e167\u2013e174. https:\/\/doi.org\/10.1200\/jop.2013.001215","journal-title":"J Oncol Pract"},{"unstructured":"U.S Department of Health & Human Services. National Viral Hepatitis Action Plan 2017-2020. https:\/\/www.hhs.gov\/hepatitis\/action-plan\/national-viral-hepatitis-action-plan-overview\/index.html. Accessed April 14, 2020","key":"5456_CR31"},{"unstructured":"World Health Organization Global Hepatitis Report 2017. http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/. Accessed February 6, 2019","key":"5456_CR32"},{"unstructured":"Owens, D. K., et al. (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. details available at https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2762186","key":"5456_CR33"},{"key":"5456_CR34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, Mermin J, Ward JW, Ryerson AB (2019) Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology 69:1020\u20131031. https:\/\/doi.org\/10.1002\/hep.30297","journal-title":"Hepatology"},{"key":"5456_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/cam4.988","volume":"6","author":"X Liu","year":"2017","unstructured":"Liu X, Chen Y, Wang Y, Dong X, Wang J, Tang J, Sundquist K, Sundquist J, Ji J (2017) Cancer risk in patients with hepatitis C virus infection: a population-based study in Sweden. Cancer Med 6:1135\u20131140. https:\/\/doi.org\/10.1002\/cam4.988","journal-title":"Cancer Med"},{"key":"5456_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jhep.2015.04.021","volume":"63","author":"RD Allison","year":"2015","unstructured":"Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, Gordon SC, Holmberg SD, Chronic Hepatitis Cohort Study I (2015) Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol 63:822\u2013828. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.021","journal-title":"J Hepatol"},{"key":"5456_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41395-018-0383-2","volume":"114","author":"HA Torres","year":"2019","unstructured":"Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP (2019) Sofosbuvir-based therapy in hepatitis C virus-infected Cancer patients: a prospective observational study. Am J Gastroenterol 114:250\u2013257. https:\/\/doi.org\/10.1038\/s41395-018-0383-2","journal-title":"Am J Gastroenterol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05456-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:03:35Z","timestamp":1618877015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05456-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5456"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05456-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Jessica P. Hwang reports grants from Gilead and Merck. Harrys A. Torres is or has been the principal investigator for research grants from Gilead Sciences, Inc., and Merck & Company, Inc., with all funds paid to The University of Texas MD Anderson Cancer Center. He also is or has been a paid scientific advisor for Gilead Sciences, Inc., Merck & Company, Inc., and Dynavax Technologies; the terms of these arrangements are being managed by The University of Texas MD Anderson Cancer Center in accordance with its conflict-of-interest policies. Anna S. Lok reports receiving research grants paid to the University of Michigan from Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, and TARGET Pharma Solutions and has served on an advisory board of Gilead Sciences. Maria E. Suarez-Almazor reports receiving consultant fees (\u2264\u200910,000 USD) Pfizer, Inc., AbbVie, Eli Lilly, Agile Therapeutics, and Amag Pharmaceuticals as well as a research grant from the Agency for Health Care Research and Quality. Erich M. Sturgis reports a grant from Roche Diagnostics. All other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}